JPRN-UMIN000017115已完成未知
Inverse Probability of Treatment Weighting Analysis of Upfront Surgery versus Neoadjuvant Chemoradiotherapy followed by Surgery for Pancreatic Adenocarcinoma with Arterial Abutment - NACRT for PDAC abutted with the artery
Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine0 个研究点目标入组 92 人开始时间: 2015年4月13日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 92
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Resectable or unresectable pancreatic cancer (NCCN criteria) (2)Tumors with encasement or stenosis of the arteries, those abutted with the celiac axis, and those only defined as BR diseases because of the superior mesenteric vein/PV factor (3) Hematologic, renal, hepatic and respiratory dysfunction (4)Active infections (5) Severe cardiac disorder, renal disorder, liver disorder, ulcer with bleeding, intestinal tract paralysis, uncontrollable diabetes mellitus (6) Presence of pleural effusion or ascites requiring drainage (7)Pregnant females or nursing mothers who can not stop lactation. Patients or partners, who don't attempt to doing contraception during the study period. (8) Severe mental disorder (9) Severe drug hypersensitivity (10) As determined by the principal investigator or the sub-investigator the subject is not adequate to participate in the trial.
研究者
相似试验
尚未招募
不适用
A Study of Injections of Pegfilgrastim in Healthy, Adult Human Subjects.CTRI/2018/02/011700Intas Pharmaceuticals Ltd
已完成
1 期
A comparative pharmacokinetic and pharmacodynamic study of insulin aspart protamine suspension administered as subcutaneous injection in healthy subjects.CTRI/2023/07/055238Mankind Pharma Limited, India36
进行中（未招募）
1 期
A research study to compare different doses of a new investigational medicinal product for treatment of certain patients with Duchenne muscular dystrophyMedDRA version: 20.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersDuchenne Muscular DystrophyEUCTR2018-001762-42-GBSarepta Therapeutics, Inc.122
进行中（未招募）
1 期
A research study to compare different doses of a new investigational medicinal product for treatment of certain patients with Duchenne muscular dystrophyDuchenne Muscular DystrophyMedDRA version: 20.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2018-001762-42-CZSarepta Therapeutics, Inc.154
进行中（未招募）
1 期
A research study to compare different doses of a new investigational medicinal product for treatment of certain patients with Duchenne muscular dystrophyMedDRA version: 20.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersDuchenne Muscular DystrophyEUCTR2018-001762-42-SISarepta Therapeutics, Inc.154